Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Observational Study
. 2018;14(2):123-129.
doi: 10.2174/1573396314666180124101059.

Efficacy of Supplementation with Iron Sulfate Compared to Iron Bisglycinate Chelate in Preterm Infants

Rossana Bagna  1 , Elena Spada  2 , Raffaela Mazzone  3 , Paola Saracco  4 , Tatiana Boetti  5 , Elena Andrea Cester  1 , Enrico Bertino  1 , Alessandra Coscia  1
Affiliations
Observational Study

Efficacy of Supplementation with Iron Sulfate Compared to Iron Bisglycinate Chelate in Preterm Infants

Rossana Bagna et al. Curr Pediatr Rev. 2018.

Abstract

Background: Strategies to prevent anaemia in preterm infants include drawing fewer blood samples, the use of recombinant human erythropoietin and iron supplementation. Although iron sulfate is the most commonly used pharmaceutical formulation for iron supplementation, there are few studies comparing different iron salts in infants.

Objective: This is a study of retrospective data comparison of two groups of preterm infants receiving erythropoietin to evaluate the efficacy of iron bisglycinate chelate to iron sulfate.

Subjects and methods: Three-hundred infants of gestational age ≤32 weeks were enrolled: 225 were supplemented with iron sulfate (3 mg/kg/day) and 75 were supplemented with iron bisglycinate chelate (0.75 mg/kg/day). The effect on erythropoiesis was assessed with a general linear model that estimates the response variables (values for Haemoglobin, Haematocrit, absolute values and percentage Reticulocytes, Reticulocyte Haemoglobin content) based on treatment, time, birth weight, and gestational age.

Results: Supplementation with iron bisglycinate chelate at a dose of 0.75 mg/kg/day demonstrated an efficacy comparable to iron sulfate at a dose of 3 mg/kg/day in both populations of preterm infants. The two cohorts had similar erythropoietic response, without significant differences.

Conclusions: The higher bioavailability of iron bisglycinate chelate resulted in a lower load of elemental iron, a quarter of the dose, and achieved equivalent efficacy compared to iron sulfate. Iron bisglycinate chelate may appear to be an alternative to iron sulfate in the prevention and treatment of preterm newborn anaemia.

Keywords: Iron deficiency; Preterm newborn anaemia; bisglycinate chelate; haemoglobin; iron sulfate; treatment..

PubMed Disclaimer

Figures

Fig. (1)
Fig. (1)
Selection of newborns included in the study.
Fig. (2)
Fig. (2)
Row mean and their IC (95%) of hemoglobin (a), hematocrit (b), reticulocytes (c), reticulocytes % (d), reticulocyte hemoglobin content (e) by number of test (#test) and group (Fe-bis: grey, Fe-sol: black).
See this image and copyright information in PMC

References

    1. Rao R., Georgieff M.K. Iron Therapy for Preterm Infants. Clin. Perinatol. 2009;36(1):27–42. - PMC - PubMed
    1. Lin J.C., Strauss R.G., Kulhavy J.C., et al. Phlebotomy overdraw in the neonatal intensive care nursery. Pediatrics. 2000;106(2):E19. - PubMed
    1. Rao R., Georgieff M.K. Perinatal aspects of iron metabolism. Acta Paediatr. Suppl. 2002;91(438):124–129. - PubMed
    1. Bateman S.T., Lacroix J., Boven K., et al. Anemia, blood loss, and blood transfusions in North American children in the intensive care unit. Am. J. Respir. Crit. Care Med. 2008;178(1):26–33. - PubMed
    1. Strauss R.G. Anaemia of prematurity: Pathophysiology and treatment. Blood Rev. 2010;24(6):221–225. - PMC - PubMed

Publication types